Prisms Group LLC

1. Tolmar, Inc. $162,713 76 payments
2. Eli Lilly and Company $52,475 6 payments
3. AstraZeneca UK Limited $46,683 3 payments
4. Sumitomo Pharma America, Inc. $43,605 19 payments
5. Merck Sharp & Dohme Corporation $33,954 8 payments
6. American Regent $32,417 8 payments
7. Organon LLC $19,100 5 payments
8. Novartis Pharmaceuticals Corporation $18,689 2 payments
9. AstraZeneca Pharmaceuticals LP $10,452 4 payments
10. Taiho Oncology, Inc. $9,110 3 payments

1. Tol2506a $65,655 14 payments
2. A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer $61,582 51 payments
3. Emonarcher: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, Her2+ Early Breast Cancer Who Have Completed Adjuvant Her2-Targeted Therapy $50,905 5 payments
4. CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2 $46,683 3 payments
5. A Multi-Center, Prospective, Observational Study of Patients Being Treated With Orgovyx $39,867 15 payments
6. Open-label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study $23,500 4 payments
7. Heart_FID $19,687 2 payments
8. Heart_FID $12,730 6 payments
9. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $12,042 1 payment
10. A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed,Platinum Carboplatin or Cisplatin Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer $12,000 3 payments

1. Patient care $19,100 5 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.